echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Merck's 2021H1 performance: revenue of 22 billion US dollars, K drug 8 billion US dollars, HPV vaccine growth 23%

    Merck's 2021H1 performance: revenue of 22 billion US dollars, K drug 8 billion US dollars, HPV vaccine growth 23%

    • Last Update: 2021-08-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Merck announced the second quarter of 2021 financial report on July 29, with total revenue of 22.
    029 billion US dollars in the first half of the year, a year-on-year increase of 12%
    .


    Revenue in the second quarter was approximately US$11.




    In terms of product development, Merck continues to advance its oncology product portfolio development plan, and it is expected that more than 90 potential new indications will be approved by 2028
    .


    Just this month, the US FDA approved the listing of the Merck pneumococcal 15-valent conjugate vaccine Vaxneuvance for the prevention of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, and 9V in adults over 18 years of age.


    In the development of COVID-19 therapeutic products, Merck announced in April this year that it would terminate the introduction of the immunomodulator MK-7110 (previously known as CD24Fc) project, and fully promote the development of oral antiviral drug molnupiravir (EIDD-2801/MK-4482)
    .


    Subsequently, Merck successively announced that it had signed a non-exclusive voluntary license agreement for molnupiravir with an Indian generic drug manufacturer, and reached a procurement agreement for molnupiravir with the US government


    Merck expects that its sales in 2021 will increase by 12% to 14%, and its annual revenue will be between 46.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.